Outsourced Pharma Capabilities Update: Enabling ADC & AOC Success

Outsourced Pharma Capabilities Update: Enabling ADC & AOC Success

Join Abzena’s Director of Bioconjugation & Synthetic Chemistry, Dr. Johanna Midelet, on Dec. 1st to learn about our extensive expertise in developing and manufacturing complex ADCs and AOCs.

Virtual Event Abstract | Dec. 1 at 8am PT, 11am ET, 4pm GMT

Discover the development, conjugation, analytical, and manufacturing capabilities supporting ADC & AOC programs.

Expanding into new diseases and formats increases the complexity of conjugate development, making early risk mitigation, precise manufacturing strategies, and the right CDMO expertise essential.

ADCs are advancing rapidly through new targets, payloads, and applications. Containing both biologic and small molecule components, these therapies present unique challenges for developability and lyophilization, as well as chemistry, manufacturing, and controls (CMC).

Newer conjugate modalities add another layer of complexity. Antibody-oligonucleotide conjugates (AOCs), for example, pair antibodies with oligonucleotides such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs). These larger, charged payloads introduce distinct development and analytical considerations.

As these technologies evolve, identifying liabilities early in development becomes increasingly important for focusing optimization cycles and protecting conjugate programs from expensive, late-stage surprises. In this session, CDMO presenters will discuss challenges relevant to both established and emerging conjugate programs, exploring how early attention to downstream details and a precise, flexible, science-driven approach can help overcome those obstacles.

Click Here to Register